| Akorn jumps on FDA approval. Cambridge Heart leaps on 510 k clearence. Viking ... - BioMedReports (subscription) |
|
|
BioMedReports (subscription)The Company's Phase 3 clinical program of Zerenex as a treatment for hyperphosphatemia in patients with end-stage renal disease who are on dialysis is ... read more |